Clinical trial
Mechanisms of Lipodystrophy in HIV-Infected Pateints
NCT00457665 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00457665 |
|---|---|
| Title | Mechanisms of Lipodystrophy in HIV-Infected Pateints |
| Official title | Mecahnisms of Lipodystrophy in HIV-Infected Patients |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Collaborators | Bristol-Myers Squibb Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Nelfinavir, Efavirenz |
| Enrollment | 56 |
| Start date | Feb 1, 2002 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2014 |
| First posted | Apr 6, 2007 |
| Last update posted | Jul 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: